EOLS stock forecast, quote, news & analysis
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market... Show more
Why Evolus (EOLS) Stock Is Down -14% in the Last 30 Days
Key Takeaways
- Evolus (EOLS) declined approximately 14% over the past 30 days, falling from $7.13 on June 26 to around $6.11 as of July 28, 2026.
- A newly announced 15% U.S. tariff on Korean pharmaceutical imports, including Evolus' flagship Jeuveau neurotoxin, weighed heavily on investor sentiment.
- The sell-off accelerated in mid-July, with the stock touching a low of $5.45 on July 20 before partially recovering in the final week of the period.
- Despite the 30-day decline, EOLS remains up roughly 16% over the trailing three months, reflecting a longer-term recovery from April lows.
- The company's July 8 announcement of an exclusive U.S. licensing deal for the skin-quality injectable Profhilo was strategically significant but did not offset near-term tariff concerns.
- Evolus is scheduled to report second-quarter 2026 financial results on August 5, which could serve as a pivotal catalyst for the stock.
Evolus (EOLS) Company Overview and Market Position
Evolus, Inc. is a global performance beauty company headquartered in Newport Beach, California, focused on building a differentiated portfolio of aesthetic injectable brands. The company's flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is the first and only neurotoxin dedicated exclusively to aesthetics and holds approximately 14% of the U.S. toxin market. Evolus has expanded its portfolio with Evolysse, a collection of injectable hyaluronic acid gels, and most recently secured exclusive U.S. rights to Profhilo, Europe's market-leading skin-quality injectable. The company operates a customer-centric digital platform that connects practitioners and consumers through tools like the Evolus Rewards loyalty program, which reached nearly 1.5 million members in Q1 2026. With over 18,000 purchasing accounts cumulatively and a customer reorder rate of approximately 71%, Evolus has established a durable commercial footprint in the competitive medical aesthetics market.
Evolus (EOLS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, EOLS shares declined approximately 14%, sliding from a closing price of $7.13 on June 26 to roughly $6.11 by July 28. The downturn was not linear: after trading in a range near $6.90 to $7.15 through early July, the stock experienced a sharp six-session sell-off between July 8 and July 16, dropping to $5.63 before finding support. A modest recovery in the final week brought shares back above $6.00, though the stock remains well below its late-June levels. In contrast, the stock's performance over the last quarter tells a more constructive story. From a closing level near $5.27 in late April, EOLS appreciated approximately 16%, driven by a strong first-quarter earnings report that showcased a second consecutive quarter of positive adjusted EBITDA and revenue that beat consensus estimates. The quarterly gain underscores a broader recovery trend that the recent 30-day pullback has partially eroded.
What Drove EOLS Stock Price in the Last 30 Days
The primary catalyst behind the recent decline was the announcement of a 15% tariff on certain South Korean pharmaceutical products, including Jeuveau, set to take effect on September 29, 2026. During Evolus' Q1 earnings call, management acknowledged the tariff and outlined plans to build U.S. inventory ahead of the effective date while exploring longer-term mitigation strategies. Despite management's confidence that the tariff would not alter 2026 or long-term financial guidance, the market reacted negatively to the uncertainty surrounding Evolus' largest revenue driver. Broader headwinds in the medical aesthetics sector, which has faced softer consumer demand and macroeconomic pressure over the past year, compounded the tariff-driven selling. The stock's mid-July plunge also reflected a period of limited news flow between the July 8 Profhilo partnership announcement and the July 22 earnings date confirmation, leaving shares vulnerable to sector-wide sentiment shifts. Additionally, some profit-taking likely occurred after the stock's strong rally from April lows.
What Drove EOLS Stock Performance Over the Last Quarter
Over the trailing three months, EOLS posted a gain of roughly 16%, a recovery fueled by the company's Q1 2026 earnings report released in early May. Evolus reported global net revenue of $73.1 million, a 7% year-over-year increase, and achieved $6 million in positive adjusted EBITDA — its second consecutive quarter of profitability on that metric. The results validated the cost-structure improvements implemented throughout 2025 and demonstrated that Evolus could deliver profitable growth while continuing to invest in product portfolio expansion. Analysts responded favorably; Needham maintained a Hold rating while H.C. Wainwright and Stifel reiterated Buy ratings, though price targets were adjusted to reflect sector-wide macro concerns. The company also provided full-year 2026 guidance of $327 million to $337 million in net revenue with low-to-mid single-digit adjusted EBITDA margins, reaffirming a path toward sustained profitability. The quarterly rally reflected growing investor confidence in Evolus' ability to execute across multiple product categories while improving operating leverage.
Trending AI Robots
In today's dynamic trading environment, AI-driven trading tools are increasingly utilized by investors seeking data-backed market insights. Tickeron's Trending AI Robots page features a curated selection of top-performing AI trading bots from a universe of hundreds that actively trade thousands of tickers across diverse strategies and timeframes. These bots are designed to analyze market signals, technical patterns, and fundamental data in real time, offering traders a systematic approach to navigating volatility. The bots vary by strategy — including swing trading, trend following, and breakout models — and each displays performance metrics that allow users to evaluate historical effectiveness. For those tracking stocks like Evolus amid shifting regulatory and sector dynamics, exploring AI-powered trading tools can provide an additional layer of analytical support.
EOLS Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst for EOLS is the company's second-quarter 2026 earnings report, scheduled for August 5. Investors will closely monitor revenue growth trends for both Jeuveau and Evolysse, updates on the Evolus Rewards loyalty program metrics, and any revised commentary on tariff mitigation strategies. The planned fourth-quarter FDA decision on Sculpt, Evolus' mid-face hyaluronic acid filler, represents a major pipeline milestone that could significantly expand the company's addressable market. In Europe, the launch of Estyme in mid-2026 will test Evolus' international growth strategy. Macroeconomic risks remain relevant, including consumer spending on discretionary aesthetic procedures, potential recession fears, and competitive pressures from established players like AbbVie's ABBV Botox franchise. The September 29 tariff implementation date creates a hard deadline for Evolus to articulate a clear mitigation path. Additionally, analysts will assess whether the company's 2028 revenue target of $450 million to $500 million remains achievable given evolving industry dynamics. While Evolus has demonstrated improved operational discipline, the convergence of tariff uncertainty and sector headwinds makes the upcoming earnings call especially consequential.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EOLS's RSI Indicator climbs out of oversold territory
The RSI Indicator for EOLS moved out of oversold territory on July 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In of the 35 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 66 cases where EOLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 29, 2026. You may want to consider a long position or call options on EOLS as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EOLS advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
EOLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for EOLS turned negative on July 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
EOLS moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EOLS crossed bearishly below the 50-day moving average on July 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EOLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for EOLS entered a downward trend on July 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EOLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (114.943) is normal, around the industry mean (47.256). P/E Ratio (0.000) is within average values for comparable stocks, (103.786). EOLS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.832). EOLS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (1.255) is also within normal values, averaging (115.273).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of neurotoxins
Industry PharmaceuticalsGeneric